SAN DIEGO--(BUSINESS WIRE)--DexCom, Inc. (NASDAQ: DXCM), the global leader in real-time continuous glucose monitoring for people with diabetes, announced today new clinical study outcomes that further demonstrate the benefits of CGM use and offered more details about its expanding portfolio of automated insulin delivery offerings at the 59th Annual Meeting of the European Association for the Study of Diabetes held Oct.

圣地亚哥-（BUSINESS WIRE）-DexCom，Inc。（纳斯达克股票代码：DXCM），糖尿病患者实时连续血糖监测全球领导者，今天宣布了新的临床研究结果，进一步证明了CGM使用的益处，并在10月举行的欧洲糖尿病研究协会第59届年会上提供了有关其不断扩大的自动胰岛素输送产品组合的更多详细信息。

2-6, 2023 in Hamburg, Germany..

2-62023年在德国汉堡。。

The leader in real-time CGM and the clear choice for automated insulin delivery

实时CGM的领导者和自动胰岛素输送的明确选择

New results from the COMISAIR seven-year study, the longest prospective real-world CGM study ever conducted, show significant and continued reduction of HbA1c with the use of real-time CGM by people with Type 1 diabetes. Regardless of insulin delivery method, multiple daily injections or insulin pump therapy, real-time CGM has greater and statistically significant HbA1c reduction when compared to self-monitoring blood glucose over seven years.* The COMISAIR study also shows further substantial reduction in HbA1c when real-time CGM is connected to an automated insulin delivery system, specifically Tandem Control IQ.† In addition, the study showed high CGM adherence over seven years, regardless of insulin delivery method, 88.8% for those using CGM and multiple daily injections and 91.9% for those using CGM and AID.‡.

COMISAIR七年研究（有史以来最长的前瞻性现实世界CGM研究）的新结果显示，1型糖尿病患者使用实时CGM可显着持续降低HbA1c。无论采用何种胰岛素输送方法，多次每日注射或胰岛素泵治疗，与7年内自我监测血糖相比，实时CGM的HbA1c降低幅度更大且具有统计学意义。*COMISAIR研究还显示，HbA1c进一步显着降低当实时CGM连接到自动胰岛素输送系统时，特别是串联控制IQ。†此外，无论胰岛素输送方法如何，该研究显示7年内CGM依从性高，使用CGM和多次每日注射者为88.8%，使用CGM和AID者为91.9%。

With the latest data from the COMISAIR study reaffirming the effectiveness of AID in improving diabetes management, Dexcom continues to strengthen its position as the world’s most connected CGM system, announcing the Dexcom G7 CGM system will begin launching with the Tandem t:slim X2 insulin pump before the end of the year in the U.S.

随着COMISAIR研究的最新数据再次证实了帮助改善糖尿病管理的有效性，Dexcom继续加强其作为世界上连接最紧密的CGM系统的地位，宣布Dexcom G7 CGM系统将开始在美国年底之前推出串联t:slim X2胰岛素泵。

and multiple markets across Europe and Asia-Pacific. This news follows the recent launch of the Omnipod 5 Automated Insulin Delivery System connected to Dexcom G6 in the UK and Germany..

以及欧洲和亚太地区的多个市场。这条消息是在最近推出的Omnipod 5自动胰岛素输送系统连接到英国和德国的Dexcom G6。。

“Dexcom is the undisputed leader in connectivity and has safely powered AID systems for more than 1 million years of cumulative patient use,” said Jake Leach, executive vice president and chief operating officer at Dexcom. “We’ve prioritized connectivity for more than a decade, which means our CGM systems are optimized to seamlessly connect with insulin delivery and digital health partners of all kinds, giving users freedom of choice in their diabetes journey and making Dexcom the clear choice for AID.”.

Dexcom的执行副总裁兼首席运营官Jake Leach说：“Dexcom是连接领域无可争议的领导者，拥有超过100万年累积患者使用的安全供电辅助系统。“十多年来，我们一直在优先考虑连通性，这意味着我们的CGM系统经过优化，可与胰岛素输送和各种数字健康合作伙伴无缝连接，使用户在糖尿病旅程中可以自由选择，并使Dexcom成为援助的明确选择“。

The CGM brand for people with Type 2 diabetes

CGM品牌适用于2型糖尿病患者

In addition to the successful results from the COMISAIR study, a new single site study with Jackie Elliot, PhD, FRCP, as the primary investigator, shows use of the Dexcom ONE CGM system by people with both Type 1 and Type 2 diabetes on intensive or basal insulin leads to significant HbA1c reduction.2 The Dexcom ONE prospective study shows use of Dexcom ONE in Type 2 subjects reduced HbA1c from 10.1% to 8.5% over three months and further reduced HbA1c to 8.3% at six months..

除了COMISAIR研究的成功结果之外，FRCP的Jackie Elliot博士作为主要研究者进行了一项新的单点研究，显示1型和2型糖尿病患者使用Dexcom ONE CGM系统对强化或基础胰岛素导致HbA1c显着降低.2 Dexcom ONE前瞻性研究显示，在2型受试者中使用Dexcom ONE可将HbA1c从10.1%降低至3个月内为8.5%，6个月时HbA1c进一步降至8.3%。。

By funding and supporting new studies that explore the efficacy of real-time CGM among those with Type 2 diabetes, Dexcom is working to improve access and expand reimbursement for more people around the world, giving them the tools they need to improve their metabolic health, lead healthier lives and stop disease progression..

通过资助和支持探索2型糖尿病患者实时CGM疗效的新研究，Dexcom正致力于改善全球更多人群的获取和扩大报销，为他们提供改善代谢健康所需的工具，引领更健康的生活，阻止疾病进展。。

“Championing access to real-time CGM technology for people with all types of diabetes is central to our mission at Dexcom,” said Alex Moussa, senior vice president and general manager of EMEA & LATAM at Dexcom. “With Dexcom G7, Dexcom G6 and Dexcom ONE, we have the most complete portfolio of CGM systems for people with all types of diabetes and we continue to work on expanding access to our life-changing technology.

Dexcom EMEA＆LATAM高级副总裁兼总经理Alex Moussa说：“支持所有类型糖尿病患者获得实时CGM技术是我们在Dexcom的使命的核心。“通过Dexcom G7，Dexcom G6和Dexcom ONE，我们拥有针对所有类型糖尿病患者的最完整的CGM系统组合，我们继续致力于扩大对改变生活的技术的使用范围。

We have recently celebrated product launches and changes to reimbursement criteria that make CGM more accessible in Argentina, Australia, Belgium, Bulgaria, France and Japan. We know the extraordinary results that real-time CGM can deliver. It’s the technology everybody living with diabetes deserves.”.

我们最近庆祝了产品推出和报销标准的改变，使CGM在阿根廷，澳大利亚，比利时，保加利亚，法国和日本更容易获得。我们知道实时CGM可以提供的非凡结果。这是每个患有糖尿病的人都应该得到的技术。”。

The CGM systems for use during pregnancy

怀孕期间使用的CGM系统

A new study with Carol Levy, MD, as lead investigator, featured at EASD, shows Dexcom G7 is accurate overall during pregnancy and across all sensor wear days and all glucose ranges for pregnant women with Type 1, Type 2 and gestational diabetes.||,3 Dexcom G7 and Dexcom G6 are now the only commercially available CGM systems with clinical studies demonstrating real-time CGM is accurate when used by people with Type 1, Type 2 and gestational diabetes during pregnancy.3,4 In addition to the Dexcom G7 pregnancy accuracy study, Dr.

EASD的主要研究人员Carol Levy博士进行的一项新研究表明，Dexcom G7在怀孕期间以及所有传感器磨损日和1型，2型和妊娠期糖尿病孕妇的所有葡萄糖范围内都是准确的。| |，3 Dexcom G7和Dexcom G6现在是唯一可商购的CGM系统，临床研究表明，当怀孕期间患有1型，2型和妊娠糖尿病的人使用时，实时CGM是准确的.3,4除了Dexcom G7怀孕准确性研究，博士。

Levy also reviewed the study protocol and objectives from the AiDAPT study led by Helen Murphy, MBBChBAO, MD, FRACP, which is the largest randomized control trial of an AID system versus standard insulin delivery in pregnant women with Type 1 diabetes and early results show women using AID spend significantly more time in target glucose range than those not using AID.5.

Levy还回顾了由Helen Murphy，MBBChBAO，MD，FRACP领导的AiDAPT研究的研究方案和目标，这是AID系统与1型糖尿病孕妇标准胰岛素输送的最大随机对照试验，早期结果显示使用AID的女性在目标血糖范围内花费的时间明显多于未使用AID的女性。

Dexcom Education Sessions at EASD 2023

EASD 2023的Dexcom教育课程

Leading the Way Through the Diabetes Journey for HCPs and Patients

引领HCP和患者的糖尿病之旅

Monday, Oct. 2, 2023, 13:30-15:00 CEST, Mumbai Hall

2023年10月2日星期一，13:30-15:00 CEST，孟买大厅

Speaker: Bernhard Kulzer, MD, PhD

主讲人：Bernhard Kulzer，医学博士、博士

Dexcom G7: The German perspective

Dexcom G7：德国视角

Speaker: Jan Soupal, MD, PhD

演讲者：Jan Soupal，医学博士，博士

Dexcom real-time CGM clinical outcomes: The 7-Year COMISAIR data

Dexcom实时CGM临床结果：7年COMISAIR数据

Speaker: Carol Levy, MD, CDCES

发言人：Carol Levy，医学博士，CDCES

Dexcom CGM in pregnancy: Outcomes and accuracy – the AiDAPT study and G7 accuracy

妊娠期Dexcom CGM：结果和准确性-AiDAPT研究和G7准确性

Speaker: Jackie Elliott, PhD, FRCP

演讲者：Jackie Elliott，PhD，FRCP

Dexcom ONE: Real-world outcomes and new innovative technologies

Dexcom ONE：现实世界的成果和新的创新技术

Leading the Way with Accuracy and Connectivity

引领准确性和连通性

Tuesday, Oct. 3, 2023, 14:45-15:15 CEST, Spotlight Theatre

2023年10月3日，星期二，东部时间14:45-15:15，聚光灯剧院

Speaker: Partha Kar​, MBBS, MD, FRCP

演讲者：Partha Kar​, 医学博士，FRCP

Updates to new NICE technology assessment for AID systems

援助系统新NICE技术评估的更新

Dexcom G7 and Tandem Control IQ, coming soon

Dexcom G7和Tandem Control IQ即将推出

Speaker: Jan Soupal, MD, PhD

演讲者：Jan Soupal，医学博士，博士

New data on 7-year COMISAIR outcomes

关于7年COMISAIR成果的新数据

Real-time CGM is the technology that provides safety, convenience and precision to diabetes management

实时CGM是为糖尿病管理提供安全，方便和精确的技术

Leading the Way with the Most Device Features Designed to Support Diabetes-Related Safety and Efficacy

领先于设计用于支持糖尿病相关安全性和有效性的大多数设备功能

Friday, Oct. 6, 2023, 10:00-10:30 CEST, Spotlight Theatre

星期五，2023年10月6日，10:00-10:30 CEST，聚光灯剧院

Speaker: Tadej Battelino, MD, PhD

主讲人：Tadej Battelino，医学博士、博士

Cognitive decline and working memory complications associated with lower time in range

认知能力下降和工作记忆并发症与较低的时间范围相关

How CGM and AID systems can be used more effectively in various patient populations to improve outcomes​

如何在各种患者群体中更有效地使用CGM和AID系统来改善结果​

Speaker: Sufyan Hussain, MA, MB BChir, MRCP, PhD

演讲者：Sufyan Hussain，MA，MB BChir，MRCP，PhD

Dexcom G7 has the most device features designed to support diabetes related safety and efficacy

Dexcom G7具有最多的设备功能，旨在支持糖尿病相关的安全性和有效性

Dexcom G7 is simple to start, easy to use and helps lower the burden of diabetes management

Dexcom G7启动简单，易于使用，有助于减轻糖尿病管理的负担

Dexcom G7 has exceptional accuracy for better informed treatment decisions

Dexcom G7具有卓越的准确性，可以做出更明智的治疗决策

For more information about these presentations and to register to virtually attend the conference, visit https://easd.org.

有关这些演示文稿的更多信息并注册以实际上参加会议，请访问https://easd.org.

About DexCom, Inc.

关于DexCom，Inc。

DexCom, Inc. empowers people to take real-time control of health through innovative continuous glucose monitoring (CGM) systems. Headquartered in San Diego, Calif., and with operations across Europe and select parts of Asia/Oceania, Dexcom has emerged as a leader of diabetes care technology. By listening to the needs of users, caregivers, and providers, Dexcom works to simplify and improve diabetes management around the world.

DexCom，Inc。通过创新的连续血糖监测（CGM）系统，使人们能够实时控制健康。Dexcom总部设在加利福尼亚州圣地亚哥，在欧洲和亚洲/大洋洲的部分地区开展业务，已成为糖尿病护理技术的领导者。通过听取用户，护理人员和提供者的需求，Dexcom致力于简化和改善全球糖尿病管理。

For more information on Dexcom, visit www.dexcom.com..

For more information on Dexcom, visit www.dexcom.com..

Category: IR

类别：IR

*7.1% (MDI+rtCGM) vs. 7.7% (MDI+SMBG). †6.6% (AID – Tandem Control IQ) vs. 7.7% (CSII+SMBG). ‡88.8±7% (MDI+CGM) and 91.9±4.1% (AID+CGM). ||Dexcom G7 overall accuracy in pregnancy as measured by %20/20 agreement rate was 92.5% for all women with diabetes (T1, T2 and GDM).

*7.1%（MDI+rtCGM）与7.7%（MDI+SMBG）†6.6%（辅助串联控制IQ）与7.7%（CSII+SMBG）88.8±7%（MDI+CGM）和91.9±4.1%（AID+CGM）||对于所有糖尿病女性（T1，T2和GDM），以%20/20协议率衡量的Dexcom G7妊娠总体准确率为92.5%。

1 Soupal, J. Dexcom rtCGM clinical outcomes: The 7-Year COMISAIR data. Presented at EASD, 2023; October 2. Hamburg, Germany. 2 Elliott, J. Dexcom ONE: Real-world outcomes and new innovative technologies. Presented at EASD, 2023; October 2. Hamburg, Germany. 3 Levy, C. Dexcom CGM in pregnancy: Outcomes and accuracy – the AiDAPT study and G7 accuracy.

1 Soupal，J。Dexcom rtCGM临床结果：7年COMISAIR数据。提交给EASD，2023年；10月2日。德国汉堡。2 Elliott，J。Dexcom ONE：现实世界的成果和新的创新技术。提交给EASD，2023年；10月2日。德国汉堡。3 Levy，C。Dexcom妊娠CGM：结果和准确性-AiDAPT研究和G7准确性。

Presented at EASD, 2023; October 2nd. Hamburg, Germany. 4 Castorino K, et al. Performance of the Dexcom G6 Continuous Glucose Monitoring System in Pregnant Women with Diabetes. Diabetes Technol Ther. 2020;22(12):943-947. 5 Murphy, H. AiDAPT study. Presented at ADA, 2023; June 25. San Diego, CA; USA..

提交给EASD，2023年；10月2日。德国汉堡。4 Castorino K，et al。Dexcom G6连续血糖监测系统在糖尿病孕妇中的表现。糖尿病技术。2020;22（12）：943-947。5 Murphy，H。AiDAPT研究。提交给艾达，2023年；6月25日。圣地亚哥，加利福尼亚州；美国。。

Dexcom, Dexcom Follow, Dexcom Clarity, and Dexcom Share are registered trademarks of Dexcom, Inc. in the U.S., and may be registered in other countries. ©2023 Dexcom, Inc. All rights reserved.

Dexcom，Dexcom Follow，Dexcom Clarity和Dexcom Share是Dexcom，Inc。在美国的注册商标，可以在其他国家注册。©2023 Dexcom，Inc。保留所有权利。